Perspective

The Pharmacogenomics Journal (2009) 9, 1–13. doi:10.1038/tpj.2008.14

The impact of microRNAs and alternative splicing in pharmacogenomics

F Passetti1, C G Ferreira2 and F F Costa3

  1. 1Laboratory of Bioinformatics and Computational Biology, Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer, Rio de Janeiro, Brazil
  2. 2Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer, Rio de Janeiro, Brazil
  3. 3Cancer Biology and Epigenomics Program, Children's Memorial Research Center, Northwestern University's Feinberg School of Medicine, Chicago, IL, USA

Correspondence: Dr FF Costa, Cancer Biology and Epigenomics Program, Children's Memorial Research Center, Northwestern University's Feinberg School of Medicine, 2300 Children's Plaza, Box 220, Chicago, IL 60614-3394, USA. Tel.: +1 773 8804000x57312; Fax: +1 773 7556551; E-mail: fcosta@childrensmemorial.org

Keywords:

polymorphisms, miRNAs, alternative splicing, drug metabolism, drug resistance, complex diseases and therapy

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

REVIEWS

Genetic variation in microRNA networks: the implications for cancer research

Nature Reviews Cancer Review (01 Jun 2010)

MicroRNA biogenesis: coordinated cropping and dicing

Nature Reviews Molecular Cell Biology Review (01 May 2005)

See all 23 matches for Reviews

NEWS AND VIEWS

Not miR-ly a splicing factor: hnRNP A1 succumbs to microRNA temptation

Nature Structural & Molecular Biology News and Views (01 Jul 2007)

Ribonucleoprotein dynamics connects mRNA networks with drug mechanisms

Molecular Systems Biology News and Views (28 Jul 2009)

RESEARCH

Surrogate Endpoints for the Treatment of Venous Leg Ulcers

Journal of Investigative Dermatology Original Article

See all 18 matches for Research